Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

Overview

This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2011

Detailed Description

The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.

Interventions

  • Drug: alfentanil
    • Alfentanil is administered intravenously at the end of surgery.

Arms, Groups and Cohorts

  • Experimental: alfentanil
    • patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods

Clinical Trial Outcome Measures

Primary Measures

  • Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults
    • Time Frame: 6 months

Secondary Measures

  • Number of patient with airway complication
    • Time Frame: after administration of alfentanil and within 1 min of LMA removal

Participating in This Clinical Trial

Inclusion Criteria

1. ASA I and II patients 2. Age 18 to 49 years old 3. Minor elective day care surgery (> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids. Exclusion Criteria:

1. Potential difficult airway 2. Reactive airway disease or sign and symptoms of upper respiratory tract infection. 3. History of cardiac, pulmonary and renal diseases 4. Body Mass Index > 30 kgm2. 5. Risk of aspiration. 6. Poor dentition with high risk of damage. 7. Patient refusal.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 49 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Malaya
  • Collaborator
    • Malaysian Society of Anaesthesiologists
  • Provider of Information About this Clinical Study
    • Principal Investigator: Lee Chew Kiok, University of Malaya – University of Malaya
  • Overall Official(s)
    • Lee Chew Kiok, MBBS, Principal Investigator, Department of Anaesthesiogy, UMMC.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.